Humanized anti-NGF mab (Lay Line Genomics/AbbVie)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHumanized anti-NGF mab (Lay Line Genomics/AbbVie)

Drug Alias Namehumanized anti-NGF antibody (Lay Line Genomics)humanized anti-nerve growth factor antibody (Lay Line Genomics)HU αD11Hu-alpha-D11ABT-110 +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionBeta-nerve growth factor inhibitors

TargetsBeta-nerve growth factor

Therapy Area/IndicationsLow Back PainPainOsteoarthritis, Knee

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesLay Line Genomics

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPangenetics Lay Line Genomics Abbvie Inc

Active IndicationsN/A

Inactive IndicationsLow Back PainPainOsteoarthritis, Knee

Other Information

ATC CodeN/A